CA-SEOUL-SEMICONDUCTOR
15.9.2020 11:40:04 CEST | Business Wire | Press release
Seoul Semiconductor Co., Ltd. (“Seoul”) (KOSDAQ 046890), a leading global innovator of LED products and technology, announced that it has successfully obtained a permanent injunction in a patent infringement lawsuit against The Factory Depot Advantages, Inc. (“Factory Depot”) that sold Philips electronic products and Feit lighting products.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200915005617/en/
The U.S. District Court for the Central District of California issued a permanent injunction against the sales of a Philips signage display product manufactured by an affiliate of TPV Technology, the world’s largest manufacturer of computer monitors. This Philips brand product incorporated LED packages informed of products from Lextar Electronics, a Taiwanese LED maker. There was no dispute in the permanent injunction order that the accused products infringed Seoul’s patents. Seoul previously obtained another permanent injunction judgment against the sales of a Philips brand LED TV in a patent infringement lawsuit filed against Fry’s Electronics.
This permanent injunction also prohibits the sale of certain filament LED bulbs of Feit Electronics. Seoul is the only licensed filament LED component supplier under the Regents of the University of California’s (Santa Barbara) filament LED patents. In recent years, Seoul has actively pursued enforcement against products suspected of infringing its patents. As a result, Seoul and its affiliates have obtained six (6) permanent injunctions, including two recall orders, of infringing products during the past three years.
Seoul is the only company in the world that has developed lighting products in all wavelength ranges, including an infrared (IR) laser diode for 1400 nm VCSEL and 200 nm UV LEDs. Seoul and its subsidiary, Seoul Viosys Co., Ltd. have invested more than $1 billion in R&D and have rights to more than 14,000 patents, resulting in Seoul’s selection as a world top patent power company by IEEE.
Seoul Viosys began manufacturing UV LEDs with Japan’s Nitride Semiconductor. In 2005, it acquired SETi. Seoul Viosys has mass-produced the world's first UV LED in a 200-400 nm range with Violeds technology. Seoul Viosys has been using its technology to protect from viruses and provide clean air, including working on technology applications that will sterilize coronavirus in a matter of seconds.
“Intellectual property is an incredible tool that allows people to break through class barriers and enable small businesses and young entrepreneurs to compete with anyone, even global conglomerates. Since industrial revolution, infant mortality rate has declined from 43% to 3% and supplied electricity to 85% of population all over the world. And the illiteracy rate also fell significantly,” said Seoul’s founder, Chung Hoon Lee.
“Even elementary school students ethically identify sources when using other people's content on YouTube. However, some companies abuse complicated patent laws and infringe other patents or have unlawful access. We hope that Seoul’s success story will reinforce the importance of R&D and the protection of intellectual property,” He added.
About Seoul Semiconductor
Seoul Semiconductor is the world’s second-largest global LED manufacturer, a ranking excluding the captive market, and has more than 14,000 patents. Based on a differentiated product portfolio, Seoul offers a wide range of technologies, and mass produces innovative LED products for indoor and outdoor lighting, automotive, IT products, such as mobile phone, computer displays, and other applications, as well as the UV area. The company’s world’s first development and mass production products are becoming LED industry standard and leading the global market with a package-free LED, WICOP; a high-voltage AC-driven LED, Acrich; an LED with 10X the output of a conventional LED, nPola; a cutting edge ultraviolet clean technology LED, Violeds; an all direction light emitting technology, filament LED; a natural spectrum LED, SunLike; and more. For more information, please visit www.seoulsemicon.com/en .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200915005617/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 202627.5.2026 23:00:00 CEST | Press release
TEVIMBRA plus ZIIHERA and chemotherapy demonstrated statistically significant overall survival benefit with an unprecedented seven-month improvement in first-line HER2+ GEAOral presentation at ASCO highlights benefit regardless of PD-L1 status, including in PD-L1 <1% BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from HERIZON-GEA-01 were published in The New England Journal of Medicine and will be presented in an oral presentation (Rapid Oral Abstract: 4010) at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2026, in Chicago.The HERIZON-GEA-01 clinical trial evaluated ZIIHERA® (zanidatamab) plus chemotherapy, with and without TEVIMBRA® (tislelizumab), compared with the control arm of trastuzumab plus chemotherapy as first-line treatment for advanced/metastatic HER2+ gastroesophageal adenocarcinoma (GEA). Dr. Sun Young Rha, Professor of Medical Oncology at the Yonsei Cancer Center, Yonsei Univ
Stallergenes Greer Foundation Celebrates Excellence in Allergy Innovation With 2025 Awards27.5.2026 17:22:00 CEST | Press release
The Stallergenes Greer Foundation, dedicated to advancing allergy research, fostering innovation and addressing environmental factors which impact allergies, is delighted to announce the recipients of the 2025 edition of its prestigious Science Awards for Allergy. Building on the success of the previous edition, this year’s awards recognise outstanding contributions to allergy research and patient engagement and allocate a total of €100,000 to support these initiatives. Four researchers have been selected by the Board as award recipients, each receiving €25,000 across two categories: Innovation In Treatment Awards Assoc. Professor Alexander Eggel, PhD, Department for Biomedical Research, University of Bern, and Department of Rheumatology and Immunology, University Hospital Bern, Switzerland, recognised for his research: “Improving diagnostic and therapeutic options for allergic patients”; Dr Janice A. Layhadi, PhD, Research Associate, National Heart and Lung Institute, Imperial College
Capchase Secures $200M+, as Demand for Vendor Financing in Enterprise Tech Deals Accelerates27.5.2026 16:00:00 CEST | Press release
As buyers face tighter budgets, Capchase helps technology companies close more deals faster with AI-enabled instant financing Capchase, the leading vendor financing platform for enterprise tech, today announced $200M+ in incremental funding to scale its embedded financing infrastructure globally and deploy more AI-enabled features. The funding, a mix of debt warehouse facilities and equity backed by institutional investors, reflects market validation that vendor financing has become essential infrastructure for enterprise technology companies to sell hardware and software products. As global B2B buyers face tighter budgets and greater scrutiny over large, up-front purchases, financing demand is growing. The Market Shift: Financing as a Growth Lever for B2B Tech Companies The $1.3 trillion vendor financing market has been traditionally dominated by banks and other lenders that utilize multi-thread email chains to manual doc review for underwriting. Capchase replaces those bottlenecks wi
ClickHouse Tops $250M ARR and 4,000 Customers, Launches Claude-Powered Agents at Open House 202627.5.2026 15:00:00 CEST | Press release
Annual run-rate revenue more than tripled year-over-year; new CostBench benchmark shows ClickHouse Cloud at 23x better cost-performance than the nearest cloud data warehouse ClickHouse today opened Open House 2026, its second annual user conference, with a set of announcements that mark one of the company's most active quarters since founding. ClickHouse’s serverless cloud offering has crossed over $250 million in annual run-rate revenue — more than triple a year ago — and added more than 1,000 net new customers since January, bringing its total to 4,000. To meet the demands of AI-era workloads, the company also launched ClickHouse Agents, a fully managed agentic analytics service powered by Anthropic's Claude; published CostBench, an open benchmark comparing the major cloud data warehouses on cost-performance; and introduced House Mates, its first formal partner program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260527
Wasabi and Liverpool FC Renew Multi-year Partnership to Scale Global Fan Growth27.5.2026 15:00:00 CEST | Press release
Wasabi remains official cloud storage partner of Liverpool FC during its worldwide expansion, helping fuel the Club’s global digital content strategy Wasabi Technologies, the hot cloud storage company, today announced a multi-year extension of its partnership with Liverpool Football Club (LFC), deepening its role as the club’s Official Cloud Storage Partner. The renewed deal will see Wasabi help power the next phase of LFC’s global content strategy through Wasabi AiR, the intelligent media storage service, enabling the club to move faster, scale smarter, and deliver more personalised fan experiences that bring supporters across the world closer to the club. Together, the partnership empowers LFC to create, store, find, and publish content faster, helping to deliver rapid match and social output and serve its global fanbase with richer, more dynamic storytelling. Meanwhile, LFC serves as a strategic partner in Wasabi’s worldwide expansion, with brand visibility that grows Wasabi’s partn
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
